StockWatch: Lilly Rises on Revenue Leap; Analysts High on Krystal Despite Revenue Miss
Eli Lilly (LLY) reported Q2 results that beat forecasts and raised 2026 GAAP revenue guidance to $85B-$87B. Q2 revenue rose 48% to $22.974B and net income rose 25% to $7.095B. Leerink raised its 12-month price target to $1,309. Krystal Biotech (KRYS) shares fell after a slight Vyjuvek revenue miss, though analysts cited strong patient growth.
How this was made
The 30-second read
Why it matters
LLY’s raised 2026 GAAP revenue range and strong Q2 sales growth are likely to keep expectations elevated, though EPS guidance was trimmed at the high end due to IPR&D charges from recent acquisitions. KRYS’s Vyjuvek revenue slightly missed forecasts, but the article provides specific reimbursement approvals and patient growth metrics that can support a demand-positive narrative despite reported softness.
Market read
This is a post-earnings guidance and analyst-reaction story: LLY gets a revenue guidance lift after a strong quarter, while KRYS faces a modest revenue miss but improved reimbursement and patient metrics.
What to watch
For KRYS, the revenue miss is tied to Germany pricing accruals; traders should separate accounting timing from true demand and monitor whether reimbursement talks change accrual behavior going forward.
Background
The piece frames LLY’s move as a post-Q2 earnings and guidance update driven by tirzepatide (Mounjaro, Zepbound) and discusses KRYS’s Vyjuvek revenue optics amid Germany reimbursement accruals.
Ticker impact
Eli Lilly raised 2026 GAAP revenue guidance to $85B-$87B after Q2 revenue jumped 48% and EPS beat consensus.
Likely continued upside bias while traders focus on raised revenue range and Mounjaro/Zepbound momentum; watch for EPS margin sensitivity from acquisition charges.
The article provides specific guidance changes, Q2 revenue/EPS beats, and the stated reason for the EPS high-end reduction, which directly informs valuation and expectations.
Krystal Biotech shares fell after Vyjuvek Q2 revenue of $119.222M missed consensus, but analysts highlighted robust underlying demand and reimbursement progress.
Near-term volatility likely, with sentiment improving if investors believe accrual-driven softness will not persist.
The article includes the revenue miss magnitude, the Germany price-accrual explanation, and concrete reimbursement/patient metrics that can change forward demand expectations.
Market effects
Reinforces GLP-1 obesity demand strength and highlights how reimbursement dynamics can drive gene-therapy revenue optics.
For LLY, non-U.S. Mounjaro sales strength is emphasized; for KRYS, Germany accrual timing affects reported European revenue.
Supports broader investor focus on obesity franchise growth and on reimbursement-linked revenue recognition in rare-disease gene therapies.
Counterpoint
LLY’s EPS high-end guidance was lowered due to acquisition-related IPR&D charges, which could signal margin pressure if similar charges recur or if growth slows.
Key entities
- companyEli Lilly
Raised 2026 GAAP revenue guidance after Q2 results; tirzepatide sales drove revenue growth.
- companyKrystal Biotech
Vyjuvek Q2 revenue slightly missed consensus; analysts cited reimbursement accrual dynamics and robust patient growth.
- productVyjuvek
Krystal’s marketed gene therapy for dystrophic epidermolysis bullosa, with revenue affected by Germany pricing accruals.
- productsMounjaro and Zepbound
Lilly’s tirzepatide therapies driving Q2 revenue growth and guidance raise.
